echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > YichenYun Health completed tens of millions of yuan A round of financing, infection prevention to save medical expenses (2020 founder Guangdong Biomedicine)

    YichenYun Health completed tens of millions of yuan A round of financing, infection prevention to save medical expenses (2020 founder Guangdong Biomedicine)

    • Last Update: 2020-09-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: Cloud health new industry, financing opportunities increased significantly! Guangzhou Yichen Cloud Health Technology Co., Ltd. (IchenYun Health) recently completed tens of millions of yuan round of financing, led by Guangzhou Danyu Venture Capital Fund Partnership (Limited Partnership), Guangzhou Chengming Chen Equity Investment Fund Enterprise (Limited Partnership), Tsingyuan VenturesILP follow-up investment.
    this round of financing will be mainly used for plant construction, clinical trials and product declaration.
    is headquartered in Guangzhou, China, with research and development centers and subsidiaries in Silicon Valley, USA.
    Yichen Cloud Health is committed to the prevention of in-hospital infections with innovative technologies, with its own research and development technology and a number of global patents, products for the world, designed to serve more patients and care for human health.
    according to the "Hospital Control Market Analysis Report" published by Arterial Network, 4 million hospital infections occur in China each year, and the direct economic losses caused by each hospital infection in China's general hospitals amount to 11,229 yuan to 33,187 yuan.
    hospital infection is becoming more and more serious, more and more attention, but there are few related products.
    this end, Yichenyun Health focused on hospital infection prevention and control, first developed catheter-related blood flow infection prevention control device (CRBSI prevention control device) and newborn umbilical cord care device.
    screening more than a dozen projects, and finally selected catheter-related blood flow infection prevention and control research and development of catheter-related blood flow infection prevention control device and newborn umbilical cord care device, is Yichenyun health after repeated deliberation to make the decision.
    , CEO of Yichen Yun Health, explains, "First, I have my own medical background and know that catheter-associated blood flow infections are tricky.
    it not only prolongs hospital stays, increases medical costs, but also results in high mortality rates among patients.
    " to blood flow infection as an example, the incidence of blood flow infection in the United States is 5.3 cases / thousand catheter days, and blood flow infection will cause diasceral blood clotting, acute heart failure and other serious complications, mortality rate of 25%-30%.
    addition, the number of hospital days for patients could be extended by 7-15 days, which would cost the U.S. health care system an additional $20 billion to $30 billion a year.
    second, Dr. Jiang Qiong-orange, in his involvement in other catheter-related projects, learned that there is a lack of solutions on the market and that catheter-induced infection rates are high.
    2012 study, 60 per cent of health care workers were unable to do six-step washing, wearing masks in wards, and washing their hands after contact with medical records and patient items.
    in the actual medical work, whether doctors, nurses or medical technicians have irregular operation, which also results in a high incidence of catheter-related blood flow infection and other hospital infections.
    third, the United States attaches great importance to catheter-related blood flow infection and other hospital infections, so far, the United States has been for catheter-related blood flow infection prevention and control for more than 10 years.
    infections, such as catheter-related blood-flow infections, cost the U.S. health care system an additional $20 billion to $30 billion a year, and the U.S. health care system is increasingly concerned about in-hospital infections.
    , the U.S. Centers for Disease Control and Prevention (CDC) has published guidelines for preventing catheter-associated blood flow infections and has updated several editions.
    CDC and hospital management have zero tolerance for catheter-related blood flow infections and have developed strict monitoring and reporting procedures, ratings, rewards, punishments, reimbursements, etc.
    , Yichen Yun Health assessed the market capacity of catheter-related blood flow infections and found that this is a huge market.
    According to YichenYun Health estimates, catheter-related blood flow infection in the global market is about 40 billion U.S. dollars, the Chinese market is 6-10 billion U.S. dollars, its future CAGR of 12%.
    (corporate pictured), the founding team selected the catheter-associated blood flow infection prevention control device project after screening more than a dozen items.
    In fact, catheter-related blood flow infection has plagued the United States for many years, related entrepreneurs, innovators are from the catheter aspect of the article, Yichenyun Health after consulting a large number of data found that this direction is not accurate, because catheter-related infection more than 65% of the incidence of infection of the skin around the catheter.
    therefore, Yichen yun health changed the way of thinking, the prevention and control of puncture point infection as the focus of research direction.
    Jiang Qiong orange told Arterial.com: "After adjusting our thinking, the products we have developed have excellent results."
    " subverted the previous design concept, from the structure, materials, technology innovation Yichenyun health carrying the project participated in the 2020 founder Guangdong Biomedicine Special Competition, and won the recognition of judges and experts.
    ," said Jiang Qiong-orange, a chinese president, "This contest provides a platform for us to show our publicity and let more people know about us."
    , in the course of the competition, we know a lot of friends in the pharmaceutical industry, exchange with each other, contribute to the development of the company.
    , Guangdong Medical Valley and other event organizers helped us connect investors, industry experts, gave us a lot of advice.
    " can stand out from the many competitions, but also from the side of the Yichen cloud health excellence.
    " catheter-related blood flow infection prevention device has only two competitors worldwide, and the device is far superior in performance to competing products.
    " catheter-associated blood flow infection prevention control device is used to prevent infections that may be caused during insertion into the catheter, including cancer chemotherapy, intensive care, renal failure hemodialysis, extraintestinal nutritional support, surgery, etc.
    present, cancer chemotherapy is the largest application, the number of cancer patients is large, the need for long-term catheter insertion during chemotherapy, the possibility of catheter-related blood flow infection is higher.
    CDC has developed guidelines on catheter-associated blood flow infections, including the clinical procedures of medical personnel, the efficacy and performance of ideal medical devices, and so on."
    currently, the catheter-associated blood flow infection prevention medical devices on the market do not meet all the requirements of the guidelines, and may even have side effects, and Yichen Cloud Health's products perfectly meet the guidelines.
    ", Yichen yun health subverted the concept of product design in the past.
    past, for catheter-related blood flow infection medical devices, the relevant research and development team is from the catheter aspect, and Yichenyun health is from the prevention and control of puncture point infection.
    , because the principle is different from the past, Yichen Cloud Health in the product design on the structure of bold innovation.
    The product structure of the catheter-associated blood flow infection prevention device has changed from the original oppressive cover to the contactless window-opening type, " explains Jiang Qiong-orange, a researcher at the University of California, Beijing.
    product structure innovation, the requirements for raw materials are higher, therefore, Yichen Cloud Health has made a lot of innovations in the material to meet the structural requirements.
    , we conducted clinical trials in the United States, resulting in fewer bacteria growth and simpler product operations.
    " compared to other products to replace a time takes 15-20 minutes, Yichen cloud health catheter-related blood flow infection prevention device can be completed in 5 minutes.
    , patients are trained to use catheter-related blood flow infection prevention devices directly at home, which will greatly improve efficiency.
    it is worth mentioning that in the past, products were structurally and materially limited and not suitable for some children, infants and allergy groups.
    , Yichen Cloud Health has made design changes to make the product available to a population that includes patients who were previously unable to use the product.
    Conduct-related blood flow infection prevention device and newborn umbilical cord care device in the structure and material innovation, so that the product function and performance greatly enhanced."
    other hand, we innovate in our processes to meet structural and material innovations.
    , many aspects of innovation has become one of the core competitiveness of Yichen Cloud Health, other enterprises and teams are difficult to imitate.
    " Yichen Cloud Health's founding team is also one of its core competitiveness.
    's founding team, CEO Dr. Joan Orange Jiang graduated from Sun Yat-sen University and Stanford University in the United States, where she designed and developed a number of disruptive innovative medical products and doubled the company's profits for many years in a row, and was a successful serial entrepreneur; Hopkins University, with a master's degree in public health economics, served as Morgan Stanley. Stanley Senior Analyst: Dr. COO Tang Erhu has served as an executive at medical device multinationals Baxter and Edwards Lifescience and has more than 20 years of successful medical device self-employment.
    "Our team members pay attention to product development, transformational production, laws and regulations, market management, enterprise management and other directions, team members of the social experience, technical capabilities and market capabilities have been experienced, both rooted in China, but also international perspective, have a deep understanding of the medical industry."
    the background and expertise of our members are matched and complementary.
    is a combative and harmonious team.
    "Health Economics Research: YichenYun Health Products Save Hospitals More Than $8 Million Jiang Qiong Orange told Arterial.com that Medicare rates nearly 4,000 hospitals across the U.S. each year for infection prevention and control and publishes them on professional websites to punish unqualified hospitals.
    hospitals with excellent infection prevention and control performance will receive relevant incentives and tax benefits.
    important indicator of assessment is catheter-related infection.
    example, Centra Health Hospital, a group of three U.S. hospitals with more than 7,250 employees, provides medical care to about 380,000 people.
    2017 health economics study by the U.S. Government found that CentraHealth's use of Ichen Cloud Health products would result in more than $8 million in cost savings.
    (corporate photo) Yichen cloud health first generation products in the United States has achieved very bright results.
    Currently, the first generation of Yichen Cloud Health's catheter-related blood flow infection prevention device has been approved by the FDA in the United States, and due to the iterative product of Yichen Cloud Health Program, updating the relevant supply chain, upgrading quality control standards, the product is expected to be available in the United States in the fourth quarter of 2021 and in China within two years.
    , Yichen Cloud Health will build a sensory data platform to monitor and prevent infection in hospitals.
    addition, YichenYun Health will rely on the advantages of the biotechnology platform, based on unmet clinical needs to determine research and development plans, such as biosurgery to stop bleeding, scar reduction, rapid and efficient research and development of innovative products.
    On the 2020 Founder Guangdong Biopharmaceutical Special Competition 2020 "Creative Guangdong" Biopharmaceutical Small and Medium-sized Enterprise Innovation and Entrepreneurship Competition by the Provincial Ministry of Industry and Information Technology and the Provincial Finance Department, Guangdong Medical Valley hosted, focusing on the field of biomedicine, more than 100 projects, held a total of 5 online preliminary and 1 offline thematic finals, recommended 12 high-quality projects to participate in the provincial rema contest, recommended items into the enterprise group and the top 10.
    Guangdong Medical Valley is a medical industry cluster service provider, focusing on biopharmaceutical and medical device industry investment incubation, the first medical industry park is located in Nansha, Guangzhou, Guangzhou key projects, a total construction area of 180,000 square meters, there are now more than 180 enterprises, including 2 academician enterprises, national major projects The 13 selected companies have introduced a number of leading enterprises, including Boya, Panshengzi and Tiankoya, covering various sub-sectors such as biomedicine, gene editing, vaccines, immunotherapy, high-end medical devices, stem cells, medical industry funds, etc., and are committed to building a world-class international medical industry innovation center.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.